natgillin/translations-raw huggingface dataset:
Patients who had a BRCA mutation and were treated with Lynparza lived on average significantly longer without their disease getting worse than patients who had a BRCA mutation and were treated with placebo (a dummy treatment): 11.2 months versus 4.3 months, respectively.
Bolnice z mutacijo gena BRCA, ki so bile zdravljene z zdravilom Lynparza, so v povprečju živele značilno dlje, ne da bi se jim bolezen poslabšala, kakor bolnice z mutacijo gena BRCA, ki so prejemale placebo (zdravilo brez zdravilne učinkovine): 11,2 meseca v primerjavi s 4,3 meseca.
Patients who had both antibody-mediated rejection and T-cell-mediated rejection on the same biopsy were counted once for each category.
Bolnike, ki so ob isti biopsiji imeli z limfociti T povezano zavrnitev in s protitelesi povezano zavrnitev, so šteli enkrat v vsako kategorijo.
Patients who had evidence of at least a minor erythroid response could continue therapy until erythroid relapse, disease progression or unacceptable toxicity.
Bolniki, ki so imeli znake vsaj manjšega eritroidnega odziva, so lahko nadaljevali z zdravljenjem do eritroidnega recidiva, napredovanja bolezni ali nesprejemljive toksičnosti.
Patients who had previously received anthracycline-based adjuvant chemotherapy were treated with paclitaxel (175 mg/m2 infused over 3 hours) with or without Herceptin.
Bolnike, ki so predhodno prejemali adjuvantno kemoterapijo na osnovi antraciklinov, so zdravili s paklitakselom (175 mg/m2, infundirano v 3 urah) samim ali skupaj z zdravilom Herceptin.
Patients who had prior rituximab therapy, either as monotherapy or in combination with other medicinal products, responded to treatment with ofatumumab at a similar rate as those who had not had prior rituximab therapy.
Med bolniki, ki so predhodno dobivali rituksimab v monoterapiji ali v kombinaciji z drugimi zdravili, je bil delež odziva na zdravljenje z ofatumumabom podoben kot med bolniki, ki predhodno niso dobivali rituksimaba.
Patients who had received 0 prior VEGF/VEGFR-targeted therapy (%)
Bolniki, ki so prejeli 0 predhodnih zdravljenj, usmerjenih v VEGF/VEGFR (%)
Patients who had received 1 prior VEGF/VEGFR-targeted therapy (%)
Bolniki, ki so prejeli 1 predhodno zdravljenje, usmerjeno v VEGF/VEGFR (%)
Patients who had received murine-derived proteins before Zevalin treatment must be tested for human anti-murine antibodies (HAMA).
Bolnike, ki so pred zdravljenjem z zdravilom Zevalin prejemali mišje beljakovine, je treba testirati na prisotnost humanih protiteles proti antigenom glodavcev (HAMA-human anti-mouse antibodies).
Patients who had received prior therapy with bevacizumab or prior systemic anticancer therapy for ovarian cancer (e.g. chemotherapy, monoclonal antibody therapy, tyrosine kinase inhibitor therapy, or hormonal therapy) or previous radiotherapy to the abdomen or pelvis were excluded from the study.
Bolnice, ki so predhodno prejemale zdravljenje z bevacizumabom ali predhodno sistemsko zdravljenje za rak jajčnikov (npr. kemoterapijo, zdravljenje z monoklonskimi protitelesi, zdravljenje z zaviralci tirozin kinaze ali hormonsko zdravljenje) ali predhodno radioterapijo trebuha ali medenice, niso bile vključene v študijo.
Patients who had the following were excluded from the trial: creatinine clearance rates < 50 mL/min, NYHA Class III to IV congestive heart failure, or myocardial infarction within the last 4 months, disease progression during the treatment with a bortezomib-containing regimen, or progression during the first 3 months of initiating treatment with lenalidomide and dexamethasone, or progression at any time during treatment with lenalidomide and dexamethasone if this was the subject’s most recent line of therapy.
V preskušanje niso bili vključeni bolniki, ki so imeli: očistek kreatinina < 50 ml/min, zastojno srčno popuščanje v III. do IV. razredu po NYHA, ali miokardni infarkt v zadnjih 4 mesecih, napredovanje bolezni med zdravljenjem s shemo, ki je vključevala bortezomib, ali napredovanje v prvih 3 mesecih po začetku zdravljenja z lenalidomidom in deksametazonom, ali napredovanje kadar koli med zdravljenjem z lenalidomidom in deksametazonom, če je le-to predstavljalo zadnjo uporabljeno linijo zdravljenja za preiskovanca.
Patients who have a low or very low risk of recurrence should not receive adjuvant treatment. the treatment of adult patients with unresectable dermatofibrosarcoma protuberans (DFSP) and adult patients with recurrent and/or metastatic DFSP who are not eligible for surgery.
Bolniki z majhnim ali zelo majhnim tveganjem za ponovitev bolezni ne smejo prejemati adjuvantnega zdravljenja; zdravljenje odraslih bolnikov z neresektabilnim protuberantnim dermatofibrosarkomom (DFSP dermatofibrosarcoma protuberans) in tistih odraslih bolnikov z rekurentnim in/ali metastatskim DFSP, ki niso primerni za operacijo.
Patients who have a stable platelet count ≥ 50 x 109/l for at least 4 weeks without dose adjustment may, at the discretion of the supervising physician, self-administer Nplate solution for injection.
Bolniki, ki imajo stabilno število trombocitov ≥ 50 x 109/l vsaj 4 tedne brez prilagoditve odmerka, si lahko po presoji nadzornega zdravnika sami injicirajo zdravilo Nplate raztopina za injiciranje.
Patients who have achieved complete remission (CR/CRh*) after 2 treatment cycles may receive up to 3 additional cycles of BLINCYTO consolidation treatment, based on an individual benefits-risks assessment.
Bolniki, ki po 2 ciklusih zdravljenja dosežejo popolno remisijo (CR/CRh* – complete remission), lahko dobijo 3 dodatne cikluse konsolidacijskega zdravljenja z zdravilom BLINCYTO; odločitev za to mora temeljiti na individualni oceni koristi in tveganj.
Patients who have achieved complete remission after 2 treatment cycles may receive up to 3 additional cycles of Blincyto if the benefits outweigh the risks for the individual patient.
Bolniki, ki po dveh ciklusih zdravljenja dosežejo popolno remisijo, lahko dobijo do tri dodatne cikluse zdravljenja z zdravilom Blincyto, če za posameznega bolnika koristi odtehtajo tveganja.
Patients who have all three risk factors for PML (i.e., are anti-JCV antibody positive and have received more than 2 years of TYSABRI therapy, and have received prior immunosuppressant therapy),
Bolnike, ki imajo vse tri dejavnike tveganja za PML (tj. so pozitivni na protitelesa proti JCV in so se z zdravilom TYSABRI zdravili več kot 2 leti in so pred tem prejemali imunosupresive),
patients who have an active infection at the operation site or have had repeated infections;
bolnikih z aktivno okužbo na mestu operativnega posega ali bolniki s ponavljajočimi se okužbami;
Patients who have atrial fibrillation are also at risk of blood clots which can travel to the brain and cause a stroke.
Pri bolnikih z atrijsko fibrilacijo prav tako obstaja tveganje za nastanek krvnih strdkov, ki lahko pridejo do možganov in povzročijo kap.
Patients who have been given more ZYPREXA than they should, have experienced the following symptoms: rapid beating of the heart, agitation/aggressiveness, problems with speech, unusual movements (especially of the face or tongue) and reduced level of consciousness.
Bolniki, ki so prejeli večji odmerek zdravila ZYPREXA, kot bi smeli, so imeli naslednje simptome: hitro bitje srca, vznemirjenost/nasilnost, težave pri govoru, nenavadne zgibke (posebno v mišicah obraza ali jezika) in zmanjšano stopnjo zavesti.
Patients who have been given too much olanzapine have also experienced the following symptoms: rapid beating of the heart, agitation/aggressiveness, problems with speech, unusual movements (especially of the face or tongue) and reduced level of consciousness.
Bolniki, ki so prejeli preveč olanzapina, kot bi smeli, so imeli naslednje simptome: hitro bitje srca, vznemirjenost/nasilnost, težave pri govoru, nenavadne zgibke (posebno v mišicah obraza ali jezika) in zmanjšano stopnjo zavesti.
patients who have developed pure red cell aplasia (reduced or stopped red blood cell production) following treatment with any erythropoietin;
bolnikih, pri katerih se je po zdravljenju z eritropoetinom razvila aplazija rdečih krvnih celic (zmanjšano ali zaustavljeno tvorjenje rdečih krvnih celic);
Patients who have difficulty swallowing tablets can mix the tablet in still water (no other liquids should be used).
Bolniki, ki imajo težave s požiranjem, lahko tableto razpustijo v navadni vodi (druge tekočine niso dovoljene).
Patients who have ever had hepatitis B infection will be carefully checked by their doctor for signs of this infection you have ever had heart problems (such as angina, palpitations or heart failure) or breathing problems.
Bolnike, ki so kdaj imeli okužbo z virusom hepatitisa B, bo zdravnik skrbno spremljal glede znakov te okužbe; če ste kdaj imeli težave s srcem (npr. angino pektoris, razbijanje srca ali srčno popuščanje) ali težave z dihanjem.
Patients who have ever had hepatitis B infection will be carefully checked by their doctor for signs of this infection. you have ever had heart problems (such as angina, palpitations or heart failure) or breathing problems.
Bolnike, ki so kdaj imeli okužbo z virusom hepatitisa B, bo zdravnik skrbno spremljal glede znakov te okužbe; če ste kdaj imeli težave s srcem (npr. angino pektoris, razbijanje srca ali srčno popuščanje) ali težave z dihanjem.
Patients who have experienced a single clinical event
Bolniki, ki so imeli en klinični dogodek
Patients who have experienced anaphylactoid/anaphylactic reactions should be treated with caution when re- administering idursulfase, appropriately trained personnel and equipment for emergency resuscitation (including epinephrine) should be available during infusions.
Pri bolnikih, ki so že imeli anafilaktoidne/anafilaktične reakcije, je pri ponovni uporabi idursulfaze potrebna previdnost; med infuzijo morata biti na voljo ustrezno usposobljeno osebje in oprema za nujno oživljanje (vključno z adrenalinom).
Patients who have experienced bronchospasm, acute rhinitis, nasal polyps, angioneurotic oedema, urticaria or other allergic-type reactions after taking acetylsalicylic acid or NSAIDs including COX-2 (cyclooxygenase-2) inhibitors.
Zdravilo je kontraindicirano: za bolnike, ki so po uporabi acetilsalicilne kisline ali nesteroidnih protivnetnih zdravil, vključno z zaviralci COX-2 (ciklooksigenaze-2), doživeli bronhospazem, akutni rinitis, nosne polipe, angionevrotski edem, urtikarijo ali druge alergijske reakcije;
Patients who have experienced severe (Grade 3 or 4) vomiting in previous treatment cycles may require anti- emetic therapy.
Bolniki, ki so imeli v prejšnjih ciklih zdravljenja težave s hudim bruhanjem (stopnja 3 ali 4), bodo verjetno potrebovali antiemetično terapijo.
Patients who have experienced somnolence and/or an episode of sudden sleep onset must refrain from driving or operating machines.
Bolniki, ki so občutili zaspanost in/ali doživeli obdobje nenadnega uspavanja morajo opustiti vožnjo ali upravljanje s stroji (glejte poglavje 4.7).
Patients who have experienced somnolence and/or an episode of sudden sleep onset must refrain from driving or operating machines.
Bolniki, pri katerih se je že pojavila zaspanost in/ali epizoda nenadnega spanca, ne smejo voziti ali upravljati s stroji.
Patients Who have Failed Previous Therapy
Bolniki, pri katerih predhodno zdravljenje ni bilo uspešno
Patients who have failed previous therapy: previous partial responders and relapsers to interferon and ribavirin therapy
Bolniki, pri katerih predhodno zdravljenje ni bilo uspešno: tisti, ki so se delno odzvali na predhodno zdravljenje, in tisti, ki se jim je bolezen po zdravljenju z interferonom in ribavirinom ponovila
patients who have had a stroke or a heart attack within the last six months; patients with unstable angina and hereditary eye problems known as ‘retinal degenerative disorders’.
bolniki, ki so v zadnjih šestih mesecih doživeli možgansko kap ali srčni napad; bolniki z nestabilno angino pektoris in dednimi očesnimi težavami, znanimi kot „retinalna degenerativna obolenja“.
patients who have had haemodialysis (a blood clearance technique used in people with kidney problems).
pri bolnikih, ki so prejemali hemodializo (tehniko čiščenja krvi, ki se uporablja pri ljudeh, ki imajo težave z ledvicami).
patients who have had liver transplantation or in
pri bolnikih, pri katerih so opravili presaditev jeter ali
Patients who have had or are undergoing liver transplantation are at particular risk since the incidence of acute renal failure is high in this group.
Pri bolnikih, pri katerih so opravili ali opravljajo presaditev jeter, je tveganje še posebej visoko, saj je v tej skupini incidenca akutne ledvične odpovedi visoka.
Patients who have had previous liver or lung injury following treatment with amiodarone (another antiarrhythmic medicine) must not be given Multaq.
Bolniki, pri katerih je v preteklosti prišlo do okvare jeter ali pljuč zaradi zdravljenja z amiodaronom (drugim zdravilom proti aritmiji), ne smejo prejemati zdravila Multaq.
patients who have had severe and unexpected reactions to fluoropyrimidine therapy (a group of cancer medicines);
bolnikih, pri katerih se pojavijo resne in nepričakovane reakcije na zdravljenje s fluoropirimidini (skupino zdravil za zdravljenje raka);
patients who have hypotension (low blood pressure);
bolniki s hipotenzijo (nizkim krvnim tlakom);
Patients who have loss of vision in one eye because of non-arteritic anterior ischemic optic neuropathy (NAION), regardless of whether this episode was in connection or not with previous PDE5 inhibitor exposure (see section 4.4).
Bolniki, ki so izgubili vid na enem očesu zaradi nearteritične anteriorne ishemične optične nevropatije (NAION), tudi če ta dogodek ni bil povezan s predhodnim jemanjem zaviralcev PDE5 (glejte poglavje 4.4).
Patients who have loss of vision in one eye because of non-arteritic anterior ischemic optic neuropathy (NAION), regardless of whether this episode was in connection or not with previous PDE5 inhibitor exposure (see section 4.4).
Bolniki, ki so izgubili vid na enem očesu zaradi nearteritične anteriorne ishemične optične nevropatije (NAION), tudi če ta dogodek ni bil povezan s predhodno izpostavljenostjo zaviralcem PDE5 (glejte poglavje 4.4).
Patients who have low immunoglobulin levels in the blood after transplantation of stem cells from another person.
Bolniki, ki imajo nizke ravni imunoglobulinov v krvi po presaditvi matičnih celic druge osebe.
Patients who have poor vision or are blind must be instructed to get assistance from another person when taking Uptravi during the titration period.
Bolnikom, ki slabo vidijo ali so slepi, je treba naročiti, da naj jim v obdobju titriranja odmerka zdravila Uptravi pomaga druga oseba.
Patients who have previously discontinued treatment with tenofovir disoproxil fumarate due to renal toxicity, with or without reversal of the effects post-discontinuation, should not be treated with Stribild (see section 4.3).
Bolniki, ki so zdravljenje z dizoproksiltenofovirijevim fumaratom predhodno prekinili zaradi ledvične toksičnosti, z ustavitvijo napredovanja učinkov po prekinitvi ali brez nje, se ne smejo zdraviti z zdravilom Stribild (glejte poglavje 4.3).
Patients who have previously discontinued treatment with tenofovir disoproxil fumarate due to renal toxicity, with or without reversal of the effects post-discontinuation.
Bolniki, ki so zdravljenje z dizoproksiltenofovirijevim fumaratom predhodno prekinili zaradi ledvične toksičnosti, z ustavitvijo napredovanja učinkov po prekinitvi ali brez nje.
Patients who have previously received a hematopoietic stem cell transplant (HSCT) may be at higher risk for hepatotoxicity suggestive of veno-occlusive disease (VOD) following treatment with clofarabine (40 mg/m2) when used in combination with etoposide (100 mg/m2) and cyclophosphamide (440 mg/m2).
Bolniki s predhodno presaditvijo krvotvornih matičnih celic (hematopoietic stem cell transplant, HSCT) so lahko izpostavljeni povišanemu tveganju za hepatotoksično sugestivno venookluzivno bolezen (veno-occlusive disease, VOD) po zdravljenju s klofarabinom (40 mg/m2), kadar se le-ta uporablja skupaj z etopozidom (100 mg/m2) in ciklofosfamidom (440 mg/m2).
Patients who have problems with their liver (including hepatitis B or C infection) may be at an elevated risk of liver damage when taking Combivir.
Pri bolnikih, ki imajo težave z jetri (vključno z okužbo s hepatitisom B ali C), obstaja pri jemanju zdravila Combivir povečano tveganje za poškodbe jeter.
Patients who have problems with their liver (including hepatitis B or C infection) may be at an elevated risk of liver damage when taking Crixivan.
Pri bolnikih, ki imajo težave z jetri (vključno z okužbo s hepatitisom B ali C), obstaja pri jemanju zdravila Crixivan povečano tveganje za okvaro jeter.
Patients who have problems with their liver (including hepatitis B or C infection) may be at an elevated risk of liver damage when taking Emtriva.
Bolniki, ki imajo težave z jetri (vključno z okužbo s hepatitisom B ali C) in prejemajo zdravilo Emtriva, so izpostavljeni povišanemu tveganju za poškodovanje jeter.
Patients who have problems with their liver (including hepatitis B or C infection) may be at an elevated risk of liver damage when taking Telzir.
Pri bolnikih, ki imajo težave z jetri (vključno z okužbami s hepatitisom B ali C), obstaja pri jemanju zdravila Telzir povečano tveganje za poškodbe jeter.
patients who have received a medicine containing BMP in the past;
bolnikih, ki so v preteklosti že prejeli zdravilo s kostnim morfogenim proteinom (BMP);
Patients who have received an allogenic stem cell transplant.
Bolniki, pri katerih je bila izvedena transplantacija alogenskih izvornih celic.
Patients who have received doses higher than those recommended (see section 4.2) should be carefully monitored, since renal function impairment (including renal failure) and serum electrolyte (including calcium, phosphorus and magnesium) abnormalities have been observed.
Bolnike, ki so dobili večje odmerke od priporočenih (glejte poglavje 4.2), je treba natančno kontrolirati, ker so pri takšnih bolnikih opažali okvaro delovanja ledvic (vključno z ledvično odpovedjo) in nepravilnosti elektrolitov v serumu (vključno s kalcijem, fosforjem in magnezijem).
Patients who have received prior anthracyclines or prior radiotherapy to the chest area may be at higher risk of LVEF declines.
Pri bolnikih, ki so predhodno prejemali antracikline ali bili obsevani v predelu prsnega koša, lahko obstaja večje tveganje za znižanje LVEF.
Patients who have received taxane and anthracycline- containing regimens in the adjuvant setting within the last 12 months should be excluded from treatment with Avastin in combination with capecitabine.
Bolniki, ki so v okviru adjuvantnega zdravljenja v zadnjih 12 mesecih prejeli sheme, ki so vsebovale taksan ali antraciklin, se ne smejo zdraviti z zdravilom Avastin v kombinaciji s kapecitabinom.
Patients who have severe dermatologic reactions or soft tissue toxicity or who develop worsening reactions whilst receiving Vectibix should be monitored for the development of inflammatory or infectious sequelae (including cellulitis and necrotising fasciitis), and appropriate treatment promptly initiated.
Bolnike s hudimi dermatološkimi reakcijami ali toksičnostjo mehkih tkiv ali poslabšanjem reakcij med uporabo zdravila Vectibix morate nadzirati zaradi možnih vnetnih ali infekcijskih posledic (vključno s celulitisom in nekrotizirajočim fasciitisom) ter jim nemudoma uvesti ustrezno zdravljenje, če se pojavijo.
Patients who have severe problems with their liver, or moderate or severe kidney problems should only be given Removab treatment after careful consideration of the medicine’s benefits and risks.
Bolniki, ki imajo resne težave z jetri ali zmerne oziroma hude težave z ledvicami, naj začnejo zdravljenje z zdravilom Removab le po skrbni obravnavi koristi in tveganj zdravila.
Patients who have taken more Olanzapine Apotex than they should have experienced the following symptoms: rapid beating of the heart, agitation/aggressiveness, problems with speech, unusual movements (especially of the face or tongue) and reduced level of consciousness.
Bolniki, ki so vzeli večji odmerek zdravila Olanzapin Apotex, kot bi smeli, so imeli naslednje simptome: hitro bitje srca, vznemirjenost/agresivnost, težave pri govoru, nenavadne zgibke (posebno v mišicah obraza ali jezika) in zmanjšano stopnjo zavesti.
Patients who have taken more OLANZAPINE CIPLA than they should have experienced the following symptoms: rapid beating of the heart, agitation/aggressiveness, problems with speech, unusual movements (especially of the face or tongue) and reduced level of consciousness.
Bolniki, ki so vzeli večji odmerek zdravila OLANZAPIN CIPLA, kot bi smeli, so imeli naslednje simptome: hitro bitje srca, vznemirjenost/nasilnost, težave pri govoru, nenavadne zgibke (posebno v mišicah obraza ali jezika) in zmanjšano stopnjo zavesti.
Patients who have taken more Olanzapine Glenmark Europe than they should, have experienced the following symptoms: rapid beating of the heart, agitation/aggressiveness, problems with speech, unusual movements (especially of the face or tongue) and reduced level of consciousness.
Bolniki, ki so vzeli večji odmerek zdravila Olanzapin Glenmark Europe, kot bi smeli, so imeli naslednje simptome: hitro bitje srca, vznemirjenost/nasilnost, težave pri govoru, nenavadne zgibke (posebno v mišicah obraza ali jezika) in zmanjšano stopnjo zavesti.
Patients who have taken more Olanzapine Glenmark than they should have experienced the following symptoms: rapid beating of the heart, agitation/aggressiveness, problems with speech, unusual movements (especially of the face or tongue) and reduced level of consciousness.
Bolniki, ki so vzeli večji odmerek zdravila Olanzapin Glenmark, kot bi smeli, so imeli naslednje simptome: hitro bitje srca, vznemirjenost/nasilnost, težave pri govoru, nenavadne zgibke (posebno v mišicah obraza ali jezika) in zmanjšano stopnjo zavesti.
Patients who have taken more Olanzapine Teva than they should have experienced the following symptoms: rapid beating of the heart, agitation/aggressiveness, problems with speech, unusual movements (especially of the face or tongue) and reduced level of consciousness.
Bolniki, ki so vzeli večji odmerek zdravila Olanzapin Teva, kot bi smeli, so imeli naslednje simptome: hitro bitje srca, vznemirjenost/nasilnost, težave pri govoru, nenavadne zgibke (posebno v mišicah obraza ali jezika) in zmanjšano stopnjo zavesti.
Patients who have taken more olanzapine than they should have experienced the following symptoms: rapid beating of the heart, agitation/aggressiveness, problems with speech, unusual movements (especially of the face or tongue) and reduced level of consciousness.
Bolniki, ki so vzeli večji odmerek zdravila OLANZAPIN MYLAN, kot bi smeli, so imeli naslednje simptome: hitro bitje srca, vznemirjenost/nasilnost, težave pri govoru, nenavadne zgibke (posebno v mišicah obraza ali jezika) in zmanjšano stopnjo zavesti.
Patients who have taken more Olazax Disperzi than they should, have experienced the following symptoms: rapid beating of the heart, agitation/aggressiveness, problems with speech, unusual movements (especially of the face or tongue) and reduced level of consciousness.
Bolniki, ki so vzeli večji odmerek zdravila Olazax Disperzi, kot bi smeli, so imeli naslednje simptome: hitro bitje srca, vznemirjenost/nasilnost, težave pri govoru, nenavadne zgibke (posebno v mišicah obraza ali jezika) in zmanjšano stopnjo zavesti.
Patients who have taken more Zalasta than they should have experienced the following symptoms: rapid beating of the heart, agitation/aggressiveness, problems with speech, unusual movements (especially of the face or tongue) and reduced level of consciousness.
Bolniki, ki so vzeli večji odmerek zdravila Zalasta, kot bi smeli, so imeli naslednje simptome: hitro bitje srca, vznemirjenost/nasilnost, težave pri govoru, nenavadne zgibke (posebno v mišicah obraza ali jezika) in zmanjšano stopnjo zavesti.